Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Xvivo Perfusion Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Xvivo Perfusion hat ein durchschnittliches jährliches Gewinnwachstum von 51.1% verzeichnet, während die Branche Medical Equipment ein Gewinnwachstum gewachsen unter 6.3% jährlich einen Rückgang. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 27.6% pro Jahr. Xvivo Perfusion's return on equity is 5%, und die Nettomargen betragen 15.6%.

Wichtige Informationen

51.1%

Wachstumsrate der Gewinne

49.0%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie6.2%
Wachstumsrate der Einnahmen27.6%
Eigenkapitalrendite5.0%
Netto-Marge15.6%
Nächste Ertragsaktualisierung12 Jul 2024

Jüngste Aktualisierungen vergangener Leistungen

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Recent updates

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Calculating The Intrinsic Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Apr 09
Calculating The Intrinsic Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Should You Think About Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Now?

Mar 19
Should You Think About Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Now?

What Type Of Shareholders Own The Most Number of Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Feb 26
What Type Of Shareholders Own The Most Number of Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Have Insiders Been Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Feb 05
Have Insiders Been Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Aufschlüsselung der Einnahmen und Ausgaben

Wie Xvivo Perfusion Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

OM:XVIVO Einnahmen, Ausgaben und Erträge (SEK Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 24643100328140
31 Dec 2359892309136
30 Sep 2357324287109
30 Jun 235242725398
31 Mar 234632824779
31 Dec 224151822369
30 Sep 223703021161
30 Jun 223282318655
31 Mar 22293717158
31 Dec 21258815354
30 Sep 21233-2413565
30 Jun 21221-3713766
31 Mar 21192-4411663
31 Dec 20180-4410867
30 Sep 20182-269558
30 Jun 20194-67964
31 Mar 20220128765
31 Dec 1922159363
30 Sep 19217128657
30 Jun 1920378652
31 Mar 1919397951
31 Dec 18188137048
30 Sep 18171136845
30 Jun 18162136743
31 Mar 18153106241
31 Dec 1714866439
30 Sep 1714506040
30 Jun 1714506341
31 Mar 1714206139
31 Dec 1613825637
30 Sep 1613255634
30 Jun 1612774632
31 Mar 1612264632
31 Dec 1512054531
30 Sep 1511344233
30 Jun 1510944031
31 Mar 159833726
31 Dec 148553423
30 Sep 147963318
30 Jun 147473217
31 Mar 147173016
31 Dec 136982915
30 Sep 136453013
30 Jun 136223010

Qualität der Erträge: XVIVO hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: XVIVODie aktuellen Gewinnspannen (15.6%) sind höher als im letzten Jahr (6%).


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: XVIVOIn den letzten 5 Jahren sind die Einnahmen von 51.1% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: XVIVODas Gewinnwachstum des Unternehmens im letzten Jahr (260.8%) übertrifft seinen 5-Jahres-Durchschnitt (51.1% pro Jahr).

Erträge im Vergleich zur Industrie: XVIVO Das Gewinnwachstum im vergangenen Jahr (260.8%) übertraf das der Branche Medical Equipment 55.1%.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: XVIVODie Eigenkapitalrendite des Unternehmens (5%) wird als niedrig angesehen.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren